Table 3 Ovary and uterus related adverse events with positive signals for atorvastatin.

From: Ovary and uterus related adverse events associated with statin use: an analysis of the FDA Adverse Event Reporting System

Classification

PTs

Overall

0–18

19–39

40–59

≥ 60

N

PRR

χ2

N

PRR

χ2

N

PRR

χ2

N

PRR

χ2

N

PRR

χ2

Ovarian cysts and neoplasms

Ovarian cancer stage I

4

7.25

14.01

–

–

–

–

–

–

–

–

–

–

–

–

Ovarian germ cell teratoma benign

4

5.24

9.00

–

–

–

–

–

–

–

–

–

–

–

–

Uterine disorders (excl neoplasms)

Endometrial disorder

8

2.55

5.82

–

–

–

–

–

–

–

–

–

5

3.46

5.75

Adenomyosis

9

2.33

5.34

–

–

–

–

–

–

–

–

–

–

–

–

Endometriosis

–

–

–

–

–

–

5

4.24

9.26

–

–

–

5

4.32

8.40

Endocrine disorders of gonadal function

Androgenetic alopecia

14

18.35

163.63

–

–

–

–

–

–

12

42.36

266.11

–

–

–

Blood testosterone increased

9

3.36

11.97

–

–

–

–

–

–

5

11.77

32.85

–

–

–

Menstrual cycle and uterine bleeding disorders

Uterine haemorrhage

–

–

–

–

–

–

–

–

–

–

–

–

9

2.86

8.28

Menopause related conditions

Menopausal symptoms

–

–

–

–

–

–

–

–

–

18

3.32

25.48

–

–

–

Sexual function disorders

Dyspareunia

–

–

–

–

–

–

–

–

–

8

2.82

7.34

6

8.89

26.66

Sexual dysfunction

–

–

–

–

–

–

–

–

–

–

–

–

8

5.30

20.20

Anorgasmia

–

–

–

–

–

–

–

–

–

8

3.20

9.48

–

–

–

  1. PTs preferred terms, PRR proportional reporting ratio, χ2: chi-square, — not a positive signal.